The first AsiC system was described in 2006 by Mcnamara et al. [30] that developed completely RNA-based chimeras in which the RNA aptamer against human PSMA, A10, was covalently linked to therapeutic siRNAs targeting polo-like kinase 1 (PLK1) and BCL2, two survival genes that are overexpressed in many human cancers (Figure 3a). The gene discussed is PLK1; the disease is cancer.